Alpha Cognition Inc. (ACOG) Stock Analysis and Metrics

Alpha Cognition

NASDAQ: ACOG

$7.99 ▼ -0.24 (-2.96%)

At close: Jul 24, 2026 · 3:50 PM UTC

Financial Ratios

Market Cap145.51 Mn

P/E-7.04

P/S14.24

Div. Yield0.00

Add ratio to table…

About

Alpha Cognition Inc. is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, with a primary focus on Alzheimer’s disease. The company’s main business activities involve the development, commercial manufacturing, and commercial sales of ZUNVEYL oral tablet formulation, a next-generation acetylcholinesterase inhibitor approved for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Alpha Cognition operates within the neurodegenerative disease therapeutics industry, specifically targeting symptomatic treatments for Alzheimer’s disease and related cognitive disorders.

Alpha Cognition generates revenue primarily through the commercial sale of ZUNVEYL, its FDA-approved delayed release oral tablet formulation indicated for mild to moderate Alzheimer’s disease. The company sells ZUNVEYL through wholesalers and pharmacies nationwide, with a commercial launch announced on March 19, 2025. Revenue is derived from prescription sales of ZUNVEYL in the United States, supported by a specialty sales force targeting long-term care physicians and facilities. The company also pursues strategic partnerships, such as its licensing agreement with CMS International Development and Management Limited for ZUNVEYL in Asia, Australia, and New Zealand, which includes upfront payments, milestone payments, and future royalties on net sales.

Alpha Cognition operates through the following segments:

• ZUNVEYL Commercialization: This segment focuses on the commercial manufacturing, sales, and marketing of ZUNVEYL oral tablet formulation for the treatment of mild to moderate Alzheimer’s disease. The company has established commercial supply of ZUNVEYL in strengths of 5 mg, 10 mg, and 15 mg, with wholesalers stocked to support launch and distribution. ZUNVEYL is marketed under the brand name ZUNVEYL by Alpha Cognition and is available by prescription in pharmacies nationwide following its commercial launch on March 19, 2025. The segment employs a specialty sales force targeting long-term care physicians in the U. S., with efforts directed at securing formulary coverage with payors and negotiating agreements with pharmacy benefit managers.

• Pre-clinical Development Programs: This segment encompasses the company’s pipeline of pre-clinical assets aimed at expanding treatment options beyond mild to moderate Alzheimer’s disease. Key programs include ALPHA-1062 in combination with memantine for moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation for cognitive impairment with mild traumatic brain injury (mTBI), and ALPHA-0602, ALPHA-0702, and ALPHA-0802 (collectively referred to as Progranulin and Progranulin GEM’s) for neurodegenerative diseases such as ALS and SMA. The company has advanced ALPHA-1062 for mTBI and acute pancreatitis following the reversion of rights in January 2025, and is pursuing non-dilutive funding for ALPHA-1062 in mTBI. The segment also includes benzgalantamine sublingual formulation development for Alzheimer’s patients with dysphagia, with ongoing formulation modification and comparative pharmacokinetic studies planned.

Alpha Cognition positions itself as a developer of next-generation acetylcholinesterase inhibitors within the Alzheimer’s disease symptomatic treatment market, where it competes with established products such as Aricept (donepezil), Exelon (rivastigmine), Razadyne (galantamine), Adlarity (donepezil transdermal system), and Namzaric (donepezil and memantine combination). The company’s competitive advantages stem from ZUNVEYL’s dual mechanism of action—enhancing acetylcholine levels and nicotinic receptor sensitivity—and its enteric-coated design, which aims to minimize gastrointestinal side effects commonly associated with existing acetylcholinesterase inhibitors. Unlike many generic treatments in the market, ZUNVEYL offers a novel formulation with patent-protected delivery methods, and the company believes it can capture market share by addressing high discontinuation rates due to side effects in the current standard of care.

Alpha Cognition’s customer base consists primarily of patients with mild to moderate Alzheimer’s disease, particularly those residing in long-term care facilities who are prescribed acetylcholinesterase inhibitor therapies. The company targets long-term care physicians and nursing homes specializing in Alzheimer’s disease care, leveraging an account-based sales team to engage with prescribers and treatment teams in these settings. While specific customer names are not disclosed in the filing, the company focuses on securing coverage and reimbursement from U. S. payors, including Medicare and pharmacy benefit managers, to support patient access to ZUNVEYL in the long-term care and broader Alzheimer’s treatment markets.

Investment Thesis

▲ Bull case

The company’s prescription metrics show a clear transition from initial trial to sustained use, with 75% of active prescribers issuing repeat prescriptions and each writer averaging five to six bottles per quarter. This repeat rate indicates that ZUNVEYL is moving beyond novelty testing into a core component of therapy for Alzheimer’s patients in long term care settings. The depth of adoption is further reinforced by an 81% repeat order rate at nursing homes, where each facility averages more than six bottles per quarter. Such strong retention suggests that early commercial momentum is translating into durable demand that could support higher revenue growth than current models anticipate.
Payer access, while still early, already demonstrates a favorable foundation with two major PBMs covering 45 million lives under Medicare D contracts that carry no prior authorization requirements. The 16% downstream formulary implementation achieved to date, coupled with an 89% approval rate when the company supports prior auth submissions, signals that broader formulary placement is likely as utilization trends continue to validate safety and efficacy. Management’s focus on real world evidence generation through the BEACON, CONVERGE and RESOLVE studies is designed to accelerate this process, and the upcoming BEACON topline data expected in early Q3 could act as a catalyst for faster payer uptake.
The recent grant of two U.S. patents extends ZUNVEYL’s market exclusivity through 2045 for both Alzheimer’s disease and traumatic brain injury indications, providing a long runway for revenue generation that exceeds the typical product life cycle in neuroscience. The TBI indication alone addresses an estimated $14 billion market, offering a substantial diversification opportunity beyond the core Alzheimer’s franchise. This intellectual property shield reduces near term competitive pressure and enhances the company’s ability to pursue premium pricing strategies in both indications.
Commercial efficiency is being bolstered by the deployment of AI enabled analytics and peer to peer education tools that help the 60‑person field force identify high value prescribers and optimize territory coverage. The 93% quarter over quarter increase in “call down” prescribers demonstrates that the expanded sales team is reaching more targets with greater effectiveness, which should improve conversion rates without a proportional rise in headcount costs. These productivity gains are critical as the company seeks to scale while maintaining disciplined expense guidance.
The sublingual formulation program, with a comparative pharmacokinetic study set to initiate this quarter, has the potential to create a differentiated delivery method that could improve patient adherence and broaden the addressable population, particularly in outpatient settings where swallowing difficulties limit tablet use. Positive PK data could enable rapid clinic advancement and provide an additional lifecycle extension for ZUNVEYL, further supporting the path to operating profitability in 2027.

The company’s prescription metrics show a clear transition from initial trial to sustained use, with 75% of active prescribers issuing repeat prescriptions and each writer averaging five to six bottles per quarter. This repeat rate indicates that ZUNVEYL is moving beyond novelty testing into a core component of therapy for Alzheimer’s patients in long term care settings. The depth of adoption is further reinforced by an 81% repeat order rate at nursing homes, where each facility averages more than six bottles per quarter. Such strong retention suggests that early commercial momentum is translating into durable demand that could support higher revenue growth than current models anticipate.
Payer access, while still early, already demonstrates a favorable foundation with two major PBMs covering 45 million lives under Medicare D contracts that carry no prior authorization requirements. The 16% downstream formulary implementation achieved to date, coupled with an 89% approval rate when the company supports prior auth submissions, signals that broader formulary placement is likely as utilization trends continue to validate safety and efficacy. Management’s focus on real world evidence generation through the BEACON, CONVERGE and RESOLVE studies is designed to accelerate this process, and the upcoming BEACON topline data expected in early Q3 could act as a catalyst for faster payer uptake.
The recent grant of two U.S. patents extends ZUNVEYL’s market exclusivity through 2045 for both Alzheimer’s disease and traumatic brain injury indications, providing a long runway for revenue generation that exceeds the typical product life cycle in neuroscience. The TBI indication alone addresses an estimated $14 billion market, offering a substantial diversification opportunity beyond the core Alzheimer’s franchise. This intellectual property shield reduces near term competitive pressure and enhances the company’s ability to pursue premium pricing strategies in both indications.
Commercial efficiency is being bolstered by the deployment of AI enabled analytics and peer to peer education tools that help the 60‑person field force identify high value prescribers and optimize territory coverage. The 93% quarter over quarter increase in “call down” prescribers demonstrates that the expanded sales team is reaching more targets with greater effectiveness, which should improve conversion rates without a proportional rise in headcount costs. These productivity gains are critical as the company seeks to scale while maintaining disciplined expense guidance.
The sublingual formulation program, with a comparative pharmacokinetic study set to initiate this quarter, has the potential to create a differentiated delivery method that could improve patient adherence and broaden the addressable population, particularly in outpatient settings where swallowing difficulties limit tablet use. Positive PK data could enable rapid clinic advancement and provide an additional lifecycle extension for ZUNVEYL, further supporting the path to operating profitability in 2027.

▼ Bear case

The company’s revenue base remains highly concentrated in a single product, ZUNVEYL, which exposes it to significant risk if adoption stalls or if competitive pressures emerge from established Alzheimer’s therapies such as donepezil, rivastigmine, or newer anti amyloid antibodies. Despite strong early metrics, the overall prescription volume is still modest at 6 050 bottles for the quarter, leaving the business vulnerable to fluctuations in prescribing patterns or changes in reimbursement policies that could quickly erode the thin top line.
Payer access progress, while promising on the surface, shows limited real world penetration with only 16% of the contracted PBM book of business having implemented formulary coverage to date. This low implementation rate suggests that health plans remain cautious and may require more extensive evidence or price concessions before granting broader access, potentially delaying the anticipated revenue acceleration. The reliance on prior authorization support to achieve an 89% approval rate also indicates that residual friction persists in the reimbursement process.
Operating expenses continue to rise sharply, with Q1 2026 spend at $11.6 million, up from $10.7 million in Q4 2025 and $6.3 million in Q1 2025, reflecting aggressive investment in sales, marketing and clinical programs. The company’s guidance of $54 million to $58 million for the full year implies a continued high cash burn trajectory, and achieving operating profitability in 2027 will depend on sustaining rapid revenue growth while controlling cost inflation—a balance that has yet to be demonstrated.
Safety signals associated with galantamine, the active metabolite of ZUNVEYL, include serious skin reactions, cardiovascular effects such as bradycardia and AV block, and potential gastrointestinal bleeding, which could limit prescriber enthusiasm or trigger restrictive labeling changes. Although these risks are noted in the prescribing information, the company did not elaborate on any mitigation strategies during the call, leaving investors uncertain about how adverse event trends might impact long term adoption or payer confidence.
The traumatic brain injury indication, while cited as a $14 billion opportunity, remains unproven in clinical trials and will require substantial additional investment to generate the data needed for regulatory approval and market acceptance. The timeline for TBI development is uncertain, and any delay or unfavorable outcome could diminish the perceived value of the recent patent extensions and divert resources from the core Alzheimer’s franchise.

The company’s revenue base remains highly concentrated in a single product, ZUNVEYL, which exposes it to significant risk if adoption stalls or if competitive pressures emerge from established Alzheimer’s therapies such as donepezil, rivastigmine, or newer anti amyloid antibodies. Despite strong early metrics, the overall prescription volume is still modest at 6 050 bottles for the quarter, leaving the business vulnerable to fluctuations in prescribing patterns or changes in reimbursement policies that could quickly erode the thin top line.
Payer access progress, while promising on the surface, shows limited real world penetration with only 16% of the contracted PBM book of business having implemented formulary coverage to date. This low implementation rate suggests that health plans remain cautious and may require more extensive evidence or price concessions before granting broader access, potentially delaying the anticipated revenue acceleration. The reliance on prior authorization support to achieve an 89% approval rate also indicates that residual friction persists in the reimbursement process.
Operating expenses continue to rise sharply, with Q1 2026 spend at $11.6 million, up from $10.7 million in Q4 2025 and $6.3 million in Q1 2025, reflecting aggressive investment in sales, marketing and clinical programs. The company’s guidance of $54 million to $58 million for the full year implies a continued high cash burn trajectory, and achieving operating profitability in 2027 will depend on sustaining rapid revenue growth while controlling cost inflation—a balance that has yet to be demonstrated.
Safety signals associated with galantamine, the active metabolite of ZUNVEYL, include serious skin reactions, cardiovascular effects such as bradycardia and AV block, and potential gastrointestinal bleeding, which could limit prescriber enthusiasm or trigger restrictive labeling changes. Although these risks are noted in the prescribing information, the company did not elaborate on any mitigation strategies during the call, leaving investors uncertain about how adverse event trends might impact long term adoption or payer confidence.
The traumatic brain injury indication, while cited as a $14 billion opportunity, remains unproven in clinical trials and will require substantial additional investment to generate the data needed for regulatory approval and market acceptance. The timeline for TBI development is uncertain, and any delay or unfavorable outcome could diminish the perceived value of the recent patent extensions and divert resources from the core Alzheimer’s franchise.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,785.72 Bn	-32.10 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,895.57 Bn	0.00 Bn	56,599.40	0.11 Bn
3	ONC	BeOne Medicines Ltd.	471.35 Bn	0.00 Bn	82.13	0.96 Bn
4	NCNA	NuCana plc	279.75 Bn	0.00 Bn	-	-
5	VRTX	Vertex Pharmaceuticals Inc / Ma	120.24 Bn	0.00 Bn	9.84	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.80 Bn	0.00 Bn	4.54	1.99 Bn
7	BLTE	Belite Bio, Inc	62.51 Bn	367.72 Bn	-	-
8	ARGX	Argenx Se	57.38 Bn	0.00 Bn	12.31	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password